Edwards Lifesciences Q1 sales rise 6.2% to $1.41 billion; raises 2025 sales guidance
Edwards Lifesciences reported first-quarter 2025 sales of $1.41 billion, up 6.2% from a year earlier, and GAAP earnings per share from continuing operations of $0.62, up from $0.54. The company raised its 2025 total sales guidance to $5.7 to $6.1 billion and its TMTT sales guidance to $530 million to $550 million, while reaffirming adjusted EPS guidance of $2.40 to $2.50. Management said operating margin is expected to face pressure from the weaker dollar, announced tariffs and the expected JenaValve acquisition close.
Key points
- Q1 sales were $1.41 billion, up 6.2%; TMTT sales rose 58% to $115 million.
- GAAP diluted EPS from continuing operations was $0.62 versus $0.54 a year earlier; adjusted EPS was $0.64.
- 2025 total sales guidance raised to $5.7 to $6.1 billion; adjusted EPS guidance of $2.40 to $2.50 reaffirmed.
- Q2 2025 outlook: total sales of $1.45 to $1.53 billion and adjusted EPS of $0.59 to $0.65.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.